Assignee profile:

Lantern Pharma Inc.

City:

Dallas, Texas

Country:

United States

Published Applications:

14

Last publication date:

2026-03-26

Patent Grants:

2

Last grant date:

2022-10-18

Top Inventors for applications by Lantern Pharma Inc.

These are the the leading inventors for applications assigned to Lantern Pharma Inc.:

Recent patent applications by Lantern Pharma Inc.

Lantern Pharma Inc. based in Dallas, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2026-03-26
US20260083691A1
Human necessities

TREATING CANCERS WITH COMBINATIONS OF ANTI-CD20 ANTIBODY AND ACYLFULVENES

#2 | 2026-01-08
US20260011400A1
Physics

MACHINE LEARNING SYSTEM AND METHOD FOR PREDICTING BLOOD BRAIN BARRIER PERMEABILITY

#3 | 2026-01-08
US20260007617A1
Human necessities

METHOD FOR TREATING RENAL CELL CARCINOMA OR CANCER

#4 | 2025-05-22
US20250161247A1
Human necessities

METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS

#5 | 2025-03-27
US20250099406A1
Human necessities

TREATING CANCERS WITH COMBINATIONS OF ACYLFULVENES WITH IBRUTINIB AND/OR BORTEZOMIB

#6 | 2024-12-26
US20240428886A1
Physics

COMPUTERIZED SYSTEMS AND METHODS FOR ENSEMBLE MODEL-BASED DRUG DISCOVERY

#7 | 2024-12-05
US20240398732A1
Human necessities

Treating Cancers with Combinations of Spironolactone and Acylfulvenes

#8 | 2024-09-12
US20240299322A1
Human necessities

TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES

#9 | 2024-09-12
US20240299316A1
Human necessities

METHOD FOR TREATING CANCER WITH ACYLFULVENE AND RADIATION

#10 | 2024-03-14
US20240082181A1
Human necessities

Method for Treating Blood Cancers

#11 | 2023-12-14
US20230399285A1
Chemistry; metallurgy

ILLUDIN ANALOGS, USES THEREOF, AND METHODS FOR SYNTHESIZING THE SAME

#12 | 2023-07-06
US20230210794A1
Human necessities

Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds

#13 | 2018-12-27 ✅ Patent 11,471,431 granted on 2022-10-18
US20180369173A9
Human necessities

Increasing cancer patient survival time by administration of dithio-containing compounds

#14 | 2016-10-06 ✅ Patent 11,471,431 granted on 2022-10-18
US20160287539A1
Human necessities

Increasing cancer patient survival time by administration of dithio-containing compounds

Also check out Lantern Pharma Inc.'s (Dallas, United States) applicant profile with 15 patent applications submitted.

AssigneeID:

339022 ⎘